Atlas of Staging in Gynecological Cancer by J. Richard Smith, Guiseppe Del Priore, & Jeremiah Healy Hardcover - 150 pages Shipped in CLICK HERE Cat.# DA-ONC17 $122.70 BUY Published:  2008   ISBN:  9781846284335

• Difficult areas within each chapter are summarised reinforcing the central points and key message of each chapter
• Describes the two common staging regimes used by all units across the world, namely, the FIGO staging system and the TNM system
• Unique landscape format allows each chapter to open on the left hand side and read across the double spread, enabling the reader to see both staging systems at once

'Atlas of Staging in Gynecological Cancer' is designed to be used in conjunction with diagnostic procedures between the surgeon and the radiologist. It describes the two common staging regimes used by all units across the world, namely, the FIGO staging system and the TNM system.

The ‘landscape’ format allows each chapter to open on the left hand side and read across the double spread, enabling the reader to see both staging systems at once. Each chapter has a separate section on Epidemiology, Diagnosis, with radiological plates, Management, in tabular form, and Key Points. The book takes the reader through each gynaecologic cancer with a short text accompanying clear radiographic images with legends. Staging is also shown in pictorial form in order to aid clarity.

The book will be of particular interest to the multi-disciplinary team who looks after this group of patients namely, clinical and radiation oncologists, surgeons, pathologists, radiologists and specialist nurses, all with their respective trainees.

Contents:
Introduction. Cervical cancer. Vaginal cancer. Vulval carcinoma. Endometrial cancer. Ovarian cancer. Gestational trophoblastic disease.

Prostate Cancer Signaling Networks, Genetics, and New Treatment Strategies Edited by Richard G. Pestell, and Marja T. Nevalainen Hardcover - 430 pages Shipped in CLICK HERE Cat.# DA-ONC20 $200.85 BUY Published:  2008   ISBN:  9781588297419

• Comprehensive, with up-to-date reviews on all aspects of biology and treatment of prostate cancer
• Translational resource for clinicians and researchers
• Discusses recent advances in prostate cancer treatment
• Provides insight into future, novel treatment strategies

Award winning authors present a comprehensive review of new perspectives in prostate cancer research and open up new directions in the clinical management of prostate cancer. In, "Prostate Cancer: Signaling Networks, Genetics, and New Treatment Strategies", the authors focus on the biology, genetics, molecular signaling networks in the disease process, and recent advances in the treatment of prostate cancer. This state-of-the-art title provides key insights into cutting edge advances in prostate cancer research, such as laparoscopic radical prostatectomy, and offers a critical evaluation and discussion of opportunities for development of novel therapies for prostate cancer.

Clinical trials that have not been covered or evaluated in any other books currently available are also discussed. Invaluable to physicians and researchers, "Prostate Cancer: Signaling Networks, Genetics, and New Treatment Strategies" provides a comprehensive translational resource as well as an important source of information for prostate cancer patients.

Contents:
Histopathology and Molecular Biology of Prostate Atrophy: A Lesion Associated with Inflammation, PIN, and Prostate Cancer. Epigenetic Gene Silencing in Prostate Cancer. Inherited Genetic Changes in Prostate Cancer. Prostate Molecular Oncogenesis: Gene Deletions and Somatic Mutations. Somatic Genetic Changes in Prostate Cancer: Androgen Receptor Alterations. Androgen Receptor in Prostate Cancer Progression. Epigenetic Modification and Acetylation of Androgen Receptor Regulate Prostate Cellular Growth. Estrogen Receptor Alpha and Beta in the Regulation of Normal and Malignant Prostate Epithelium. Estrogen Action in Normal Prostate Epithelium and in Prostate Cancer. Hypoxia Inducible Factor 1 and Angiogenesis in Prostate Cancer. Signal Transduction by the Ras – MAP Kinase Pathway in Prostate Cancer Progression. Transcription Factors Stat5 and Stat3: Survival Factors for Prostate Cancer Cells. Role of PI3K-Akt and PTEN in the Growth and Progression of Prostate Cancer. New Perspectives in Prediction of Clinical Outcome of Prostate Cancer: TMPRSS2-ETS Gene Fusion in Prostate Cancer. New Directions in Radiation Therapy of Prostate Cancer: Brachytherapy and Intensity Modulated Radiation Therapy. Advances in Surgical Intervention of Prostate Cancer: Comparison of the Benefits and Pitfalls of Retropubic, Perineal and Laparoscopic Radical Prostatectomy. Targeted Therapy Trials for Prostate Cancer. New Perspectives on Chemotherapy of Prostate Cancer. Concluding Remarks: The Future of Prostate Cancer.

Lung Cancer Edited by Jack A. Roth, James D. Cox, and Waun Ki Hong Hardcover - 480 pages Shipped in CLICK HERE Cat.# JW-ONC15 $186.35 BUY Published:  2008   ISBN:  9781405151122

Lung cancer is a major cause of cancer-related deaths in men and women. However, since the first edition of Lung Cancer was published 14 years ago, rapid progress in the biology, prevention, diagnosis, and treatment of the disease has been made.

Table of Contents:

Contributors
Preface

1. Smoking Cessation
2. Lung Cancer Susceptibility Genes
3. Lung Cancer Susceptibility and Risk Assessment Models
4. The Molecular Genetics of Lung Cancer
5. Molecular Biology of Preneoplastic Lesions of the Lung
6. Detection of Preneoplastic Lesions
7. Treatment of Preneoplastic Lesions of the Lung
8. The Pathology and Pathogenesis of Peripheral Lung Adenocarcinoma Including Bronchioloalveolar Carcinoma
9. Treatment of Bronchioloalveolar Carcinoma
10. Molecular Profiling for Early Detection and Prediction of Response in Lung Cancer
11. The Role for Mediastinoscopy in the Staging of Nonsmall Cell Lung Cancer
12. Minimally Invasive Surgery for Lung Cancer
13. Extended Resections for Lung Cancer
14. Adjuvant Chemotherapy Following Surgery for Lung Cancer
15. Induction Chemotherapy for Resectable Lung Cancer
16. Image-Guided Radiation Therapy
17. Stereotactic Body Radiation Therapy for Lung Cancer
18. Proton Therapy
19. Combinations of Radiation Therapy and Chemotherapy for Nonsmall Cell Lung Carcinoma
20. New Chemotherapeutic Agents in Lung Cancer
21. Immunologic Approaches to Lung Cancer Therapy
22. Epidermal Growth Factor Receptor Inhibitors
23. Tumor Angiogenesis: Biology and Therapeutic Implications for Lung Cancer
24. Retinoids and Rexinoids in Lung Cancer Prevention and Treatment
25. Proteasome Inhibition in Nonsmall Cell Lung Cancer Therapy
26. Targeted Genetic Therapy for Lung Cancer
27. Screening for Early Detection
28. Natural Agents for Chemoprevention of Lung Cancer

Vladimir Badmaev (Sabinsa Pharmaceutical, Inc., New Jersey), Burton Dickey (The University of Texas M.D. Anderson Cancer Center), and Jonathan Kurie (The University of Texas M.D. Anderson Cancer Center).

Index

Viral Therapy of Cancer by K. J. Harrington, Richard G. Vile, and Hardev Pandha Hardcover - 432 pages Shipped in CLICK HERE Cat.# JW-ONC16 $171.80 BUY Published:  2008   ISBN:  9780470019221

This book provides an in-depth analysis of the current status of all the key viruses that are being developed as treatments for cancer. It is the first book to describe the use of viruses as oncolytic agents, killing cells directly, and it bridges the gap between bench research and clinical applications.

Viral Therapy of Cancer reviews all aspects of viral applications in the treatment of cancer, including quality, control and regulatory issues in various countries. Edited by three experts in the field of cancer gene therapy with experience in both laboratory and clinical research, this book is an invaluable resource for both basic scientists and clinicians with an interest in virology and gene therapy.

Table of Contents:

Foreword
Preface

1. Adenoviruses

1.1 Introduction
1.2 Viral structure and lifecycle
1.3 Adenoviral vectors
1.4 Targeting adenoviral vectors
1.5 Clinical applications of adenoviral gene therapy
1.6 Adenoviral vectors for immunotherapy
1.7 Adenoviral vectors for suicide gene therapy
1.8 Adenoviral vectors for gene replacement therapy
1.9 Oncolytic adenoviral therapy
1.10 Adverse outcomes of adenoviral gene therapy
1.11 Summary

References

2. Application of HSV-1 factors to the treatment of cancer

2.1 Introduction
2.2 Basic biology of HSV
2.3 Replication competent or oncolytic vectors
2.4 Replication defective vectors
2.5 Amplicons
2.6 Impediments to the efficacy of HSV vectors for cancer gene therapy
2.7 Strategies to enhance the efficacy and specificity of HSV vectors for cancer gene therapy
2.8 Summary and conclusions

References

3. Adeno-associated virus

3.1 Introduction
3.2 Biology and life cycle of AAV
3.3 AAV serotypes
3.4 Production of recombinant AAV
3.5 Gene therapy for cancer treatment
3.6 Anti-oncogenic properties of AAV
3.7 Molecular chemotherapy studies with rAAV
3.8 AAV-mediated sustained transgene expression as a potential cancer gene therapy strategy
3.9 rAAV vectors have advantages in stimulating T helper 1/cytotoxic T lymphocyte responses
3.10 rAAV vectors can be used to initiate immune responses
3.11 Altering AAV tropism for tumour-specific delivery
3.12 Clinical trials involving rAAV
3.13 Conclusion

Acknowledgements
References

4. Retroviruses

4.1 Introduction
4.2 Structure of retroviral particles
4.3 Retroviral genome
4.4 Retroviral life cycle
4.5 Retroviral vectors
4.6 Safety of retroviral vectors: insertional mutagenesis
4.7 Gene therapy of X-linked SCID
4.8 Retroviral cancer gene therapy
4.9 Immunomodulatory approaches
4.10 Conclusions

References

5. Lentiviral vectors for cancer gene therapy

5.1 Development of lentiviral vectors (LV)
5.2 Targeting of transgene expression
5.3 Host immune responses to LV and their transgene
5.4 Transgenesis
5.5 Haematopoietic stem cell gene transfer
5.6 Cancer treatment by LV
5.7 Approved clinical trials using LV
5.8 Conclusions

References

6. Poxviruses as immunomodulatory cancer therapeutics

6.1 Introduction
6.2 General features of poxvirus structure and biology
6.3 Clinically applicable poxviruses
6.4 Poxviruses as potential cancer therapeutics
6.5 Clinical experience with poxviruses
6.6 Conclusion

References

7. Oncolytic herpes simplex viruses

7.1 Introduction
7.2 Herpes simplex virology
7.3 Properties of HSV relevant to oncolytic virus therapy
7.4 Mutations giving tumour-selective replication
7.5 Oncolytic HSV expressing fusogenic membrane glycoproteins (FMG)
7.6 Prodrug activation therapy and oncolytic HSV
7.7 Combination of oncolytic HSV with immunomodulatory gene expression
7.8 Combination of conventional therapies with oncolytic HSV
7.9 Summary

Acknowledgement
References

8. Selective tumour cell cytotoxicity by reoviridae - preclinical evidence and clinical trial results

8.1 Introduction
8.2 Reovirus structure
8.3 Reovirus replication
8.4 Reovirus and human infection
8.5 Oncolytic activitiy
8.6 Mechanism of reovirus-induced cytotoxicity
8.7 Preclinical experience
8.8 Immunogeneicity
8.9 Clinical experience
8.10 Conclusions

References

9. Oncolytic vaccinia

9.1 Introduction
9.2 Biology of vaccinia virus
9.3 Tumour selectivity and antitumour effect
9.4 Improving antitumour effects through bystander effects
9.5 Immune response to vaccinia and vaccinia immune evasion strategies
9.6 Virus-driven antitumour immune response
9.7 Imaging
9.8 Current and potential clinical applications

References

10. Newcastle Disease virus: a promising vector for viral therapy of cancer

10.1 Introduction
10.2 Structure, taxonomy, pathogenicity and oncolytic properties of NDV
10.3 Human application and safety
10.4 Tumour-selective replication of NDV
10.5 Virally based cancer immunotherapy and danger signals
10.6 NDV: a danger signal inducing vector
10.7 The human cancer vaccine ATV-NDV
10.8 Pre-existing antitumour memory T cells from cancer patients and their activation by antitumour vaccination with ATV-NDV
10.9 Clinical trials of antitumour vaccination with ATV-NDV
10.10 NDV-specific recombinant bispecific antibodies to augment anti-tumour immune responses
10.11 NDV-binding bispecific fusion proteins to improve cancer specific virus targeting
10.12 Recombinant NDV as a new vector for vaccination and gene therapy
10.13 Conclusion

References

11. Vesicular stomatitis virus

11.1 Introduction
11.2 Vesicular stomatitis virus (VSV): genomic organization and life cycle
11.3 Host range and pathogenesis of VSV infection
11.4 Control of VSV infection by the innate type I interferon response
11.5 cancer cells are insensitive to type I interferon
11.6 VSV preferentially replicates in and lyses tumour cells in vitro
11.7 VSV attenuation: enhanced tumour selectivity and therapeutic index
11.8 Engineered/recombinant VSV
11.9 VSV effectively eradicates tumours in vivo
11.10 VSV and the host immune response
11.11 Host immunity vs. therapeutic efficacy
11.12 VSV is a potent vaccine
11.13 Innate sensing of VSV and the antitumour response
11.14 So what is a good oncolytic virus?
11.15 Future challenges for VSV

References

12. Measles as an oncolytic virus

12.1 Introduction
12.2 Measles virus and the consequences of natural infection
12.3 MV vaccine
12.4 MV genetics and engineering
12.5 MV receptors
12.6 Animal models for the study of MV pathogenesis and oncolysis
12.7 Oncolytic activity of MV
12.8 Mechanism of specificity
12.9 Targeting MV entry
12.10 Enhancing the oncolytic activity of MV
12.11 Interactions with the immune system
12.12 Potential specific toxicities of clinical use of replicating attenuated MV
12.13 Clinical trials
12.14 Conclusions

References

13. Alphaviruses

13.1 Introduction
13.2 RNA viruses as gene expression vectors
13.3 The biology of alphaviruses
13.4 Heterologous gene expression using alphavirus vectors
13.5 Cancer gene therapy strategies using alphavirus vectors
13.6 Alphavirus vector development for gene therapy application
13.7 Conclusions

References

14. Tumour-suppressor gene therapy

14.1 Tumour-suppressor genes
14.2 Use of tumour-suppressing genes for cancer therapy
14.3 Clinical trials of p53 gene replacement
14.4 Tumour-suppressor gene therapy in multimodality anticancer treatment
14.5 Future prospects

Acknowledgements
References

15. RNA interference and dominant negative approaches

15.1 Introduction
15.2 Oligonucleotide agents
15.3 Mechanism of RNAi
15.4 RNAi and antisense compared
15.5 siRNA design
15.6 Off-target effects
15.7 Induction of innate immunity
15.8 Methods of delivery
15.9 Antisense
15.10 Dominant negative approaches
15.11 Research applications of siRNA
15.12 Therapeutic applications of siRNA

References

16. Gene-directed enzyme prodrug therapy

16.1 Introduction
16.2 Enzyme-prodrug systems for GDEPT
16.3 Gene delivery vectors for GDEPT
16.4 Conclusions

References

17. Immunomodulatory gene therapy

17.1 Introduction
17.2 Immunotherapy strategies using viral vectors
17.3 Viruses used as viral vectors in cancer immunotherapy
17.4 Clinical trials against specific TAA
17.5 Conclusions and future prospects

References

18. Antiangiogenic gene delivery

18.1 Angiogenesis: role in tumour development and metastasis
18.2 Targeting tumour vasculature as an approach for cancer treatment
18.3 Viral vectors to deliver antiangiogenic gene products
18.4 Viral targeting
18.5 Concluding remarks

References

19. Radiosensitization in viral gene therapy

19.1 Introduction
19.2 Adenovirus
19.3 Adeno-associated viruses
19.4 Herpes simplex viruses
19.5 Enhancing the effect of radiation by delivering tumour suppressor genes
19.5 Virus-directed enzyme prodrug therapy
19.6 Conclusion

References

20. Radioisotope delivery

20.1 Introduction
20.2 History of iodine therapy
20.3 Genetic therapy
20.4 Conclusion

References

21. Radioprotective gene therapy: current status and future goals

21.1 Introduction
21.2 Organ-specific radiation protection: oral cavity/oropharynx
21.3 A potential beneficial added observation of antitumour effect of radiation protection using MnSOD-PL
21.4 HA-MnSOD effects on reducing the repopulation (cytoprotective response) induced by irradiation in tumours and the role of EGFR-TKI
21.5 MnSOD-PL treatment to ameliorate the dose limiting oesophageal toxicity of irradiation
21.6 MnSOD-PL treatment reduces pulmonary irradiation damage
21.7 MnSOD-PL systemic administration for radiation protection from TBI
21.8 Summary and future directions

References

22. Chemoprotective gene delivery

22.1 Introduction
22.2 The promise of chemoselection strategies
22.4 The limitations of chemoselection strategies
22.5 Which expression level of chemoprotective genes is appropriate?
22.6 Vector design to achieve optimal expression levels
22.7 Exploring side effects of continued transgene expression and insufficient chemoprotection
22.8 The future: inducible expression of drug resistance genes

Acknowledgements
References

Gastrointestinal Oncology, A Critical Multidisciplinary Approach by Janusz Jankowski, Richard E. Sampliner, MD, David J. Kerr, Yuman Fong, Ernest Hawk, Jaye L. Viner Hardcover - 752 pages Shipped in CLICK HERE Cat.# JW-ONC17 $357.25 BUY Published:  2008   ISBN:  9781405127837

This is the first evidence-based reference text written for the multidisciplinary team of medical professionals involved in the investigation, diagnosis and management of patients with gastrointestinal cancer.

Written by the leading international experts in the field, it sets the standard in clinical practice. It contains specially structured clinical chapters each representing a different role in the MDT - which enables clear presentation and quick reference of the contents.

Table of Contents:

1. Epidemiology of Gastroesophageal Cancer
2. Factors involved in Carcinogenesis and Prevention
3. Molecular Biology of Gastroesophageal Cancers: the Role of Mutational Analysis
4. MDT Approach to Esophageal Adenocarcinoma
5. Squamous Cancer of the Esophagus
6. Diffuse Gastric Cancer
7. Intestinal Gastric Cancer
8. Small Bowel Adenocarcinoma
9. MDT Approach to Sarcoma and Gastrointestinal Stromal Tumors
10. Rare Tumors of the Abdomen
11. Epidemiology and prevention of colorectal cancer
12. Molecular Biology
13. Screening for colorectal cancer
14. Approach to cancer of the colon and rectum
15. Approach to rare tumours/rare cancers of the colon
16. Epidemiology and Molecular Epidemiology
17. Factors involved in Carcinogenesis and Prevention
18. Molecular Biology
19. Approach to Primary Liver Cancer (Hepatoma)
20. Approach to Metastatic Liver Cancer
21. Approach to Primary Pancreatic Adenocarcinoma
22. Approach to Cholangiocarcinoma
23. GI Neuroendocrine Tumors
24. Approach to the Rare Tumors of the Liver
25. Approach to Cystic lesions of the pancreas

Index

Cancer in Children and Young People by Faith Gibson, and Louise Soanes Hardcover - 432 pages Shipped in CLICK HERE Cat.# JW-ONC18 $ 83.60 BUY Published:  2008   ISBN:  9780470058671

Much has changed since the first book Paediatric Oncology: Acute Nursing Care (1999), therefore, this new edition encompasses these changes in relation to the practice itself and the evidence that underpins it. Emphasis is placed on ensuring terminology is accurate, in keeping with the language of the current day.

The book is divided into six sections: Chemotherapy, Haematopoetic Stem Cell Transplantation, General Surgery, Radiotherapy, Late Effects of cancer therapies, and Palliative Care. There is a brief commentary at the end of each section/chapter by a ‘novice’ author but experienced practitioner, highlighting to the reader what is already known and what the section/chapter adds to their current knowledge and practice.

Table of Contents:

Chapter 1: Principles of chemotherapy
Chapter 2: Chemotherapy agents
Chapter 3: Administration of chemotherapy
Chapter 4: Side effects of chemotherapy and supportive
Chapter 5: Oncological emergencies
Chapter 6: Future trends
Commentary: Chemotherapy section.

Section 2: Haematopoetic Stem Cell Transplantation

Chapter 7: Background to HSCT procedure
Chapter 8: Preparation for bone marrow transplant
Chapter 9: Collection and infusion of bone marrow, peripheral blood stem cells and umbilical cord blood
Chapter 10: Protective isolation nursing issues
Chapter 11: Complications of stem cell transplant
Chapter 12: Discharge planning and the psychological care of the family
Chapter 13: Staff support in stem cell transplant units

Chapter 14: Further developments in stem cell transplant
Commentary: Haematopoetic Stem Cell Transplantation

Section 3: Surgery

Chapter 15: General surgery
Commentary: General surgery

Chapter 16: Neuro-oncology
Commentary: Neuro-oncology

Chapter 17: Primary bone cancer in young people
Commentary: Primary bone cancer in young people

Section 4: Radiotherapy

Chapter 18: The nature of radiotherapy
Chapter 19: Administration of radiotherapy
Chapter 20: Tumours and radiotherapy treatment
Chapter 21: Acute and sub-acute side effects of radiotherapy
Chapter 22: The role of radiotherapy and palliative care

Section 5: Late effects of cancer therapies

Chapter 23: Overview of long-term follow-up
Chapter 24: Potential physical issues following cancer treatment
Chapter 25: The role of the nurse in Long-Term Follow-Up
Chapter 26: Health promotion for Long-Term Follow-Up patients
Chapter 27: Quality of Life in long-term survivors of childhood cancer

ABC of Skin Cancer by Sajjad Rajpar, and Jerry Marsden Softcover - 80 pages Shipped in CLICK HERE Cat.# JW-ONC19 $ 46.30 BUY Published:  2008   ISBN:  9781405162197

The ABC of Skin Cancer is designed to boost GP confidence in the diagnosis and referral of skin cancer, focusing on differential diagnosis and common pitfalls. In line with the latest NICE guidelines in the UK, this book outlines best practice management in primary care, whilst also covering the Australian perspective on this cancer. Chapters on non-surgical treatment and prevention are also included.

This new highly illustrated title in the successful ABC series provides a concise, factual and practical overview of skin cancers and pre-cancerous lesions for general practitioners, junior doctors and medical students.

Table of Contents:

1. Epidemiology, aetiology and prevention of melanoma
2. Epidemiology, aetiology and prevention of non-melanoma skin cancer
3. The role of the primary care team in the management of patients with skin cancer
4. Pre-cancerous skin lesions
5. Squamous cell carcinoma
6. Basal cell carcinoma
7. Differential diagnosis of non-melanoma skin cancer
8. Benign pigmented lesions
9. Melanoma – clinical features and diagnosis
10. Melanoma – management and prognosis
11. Surgical treatment of skin cancer
12. Non-surgical treatment of skin cancer
13. Skin cancer – an Australian perspective
14. Rare skin cancers and cutaneous metastases

Skin Cancer by Robert A. Schwartz Hardcover - 536 pages Shipped in CLICK HERE Cat.# JW-ONC20 $212.70 BUY Published:  2008   ISBN:  9781405159616

The second edition of Skin Cancer: Recognition and Management is a definitive clinical reference which comprehensively examines the wide range of premalignant and malignant cutaneous disorders, including melanoma, Kaposi's sarcoma and other sarcomas, cutaneous lymphoma, cutaneous metastatic disease and cutaneous markers of internal malignancy, with emphasis on the most recent advances in diagnosis and management.

Fully revised and expanded, this new edition now includes full colour photographs and illustrations throughout to aid recognition and diagnosis, and covers the latest developments and treatment modalities. New chapters include:

• Merkel Cell Carcinoma
• Dermoscopy

Skin Cancer: Recognition and Management is a definitive clinical reference for dermatologists, oncologists, residents and any medical practitioner with an interest in skin cancer.

Table of Contents:

Contributors
Preface

1. Introduction
2. Actinic keratosis
3. Other premalignant cutaneous dysplasias
4. Bowen’s disease
5. Squamous cell carcinoma
6. Keratoacanthoma
7. Basal cell carcinoma
8. Appendageal carcinomas and cutaneous sarcomas
9. Kaposi’s sarcoma
10. Dysplastic nevus and dysplastic nevus syndrome
11. Melanoma
12. Dermoscopy for skin cancer
13. Merkel cell carcinoma
14. Dermatitic precursors of mycosis fungoides
15. Cutaneous lymphoma, leukemia, and related disorders
16. Cutaneous metastatic disease
17. Cutaneous markers of internal malignancy
18. Early oral and oropharyngeal cancer diagnosis and management
19. Histopathologic considerations in the management of skin cancer
20. Historical survey: methods used to treat skin cancer
21. Curettage and electrodesiccation
22. Cryosurgery
23. Excision of skin cancer
24. Local flap closure in the management of skin cancer
25. The role of skin grafts in the management of skin malignancies
26. Mohs micrographic surgery
27. Photodynamic therapy
28. Cutaneous cancer and radiotherapy
29. Local chemotherapy
30. Topical immunotherapy
31. Treatment of melanoma

Index

Abeloff's Clinical Oncology by Martin Abeloff, James Armitage, Jone Niederhuber, Michael Kastan, and W. Gillies McKenna Hardcover - 3,808 pages Shipped in CLICK HERE Cat.# EL-ONC7 $293.65 BUY Published:  2008   ISBN:  9780443066948

Carrying on the tradition established by its founding editor, the late Dr. Martin Abeloff, the 4th Edition of this respected reference synthesizes all of the latest oncology knowledge in one practical, clinically focused, easy-to-use volume. It incorporates basic science, pathology, diagnosis, management, outcomes, rehabilitation, and prevention – all in one convenient resource – equipping you to overcome your toughest clinical challenges. What's more, you can access the complete contents of this Expert Consult title online, and tap into its unparalleled guidance wherever and whenever you need it most!

• Equips you to select the most appropriate tests and imaging studies for diagnosing and staging each type of cancer, and manage your patients most effectively using all of the latest techniques and approaches.
• Explores all of the latest scientific discoveries' implications for cancer diagnosis and management.
• Employs a multidisciplinary approach - with contributions from pathologists, radiation oncologists, medical oncologists, and surgical oncologists - for well-rounded perspectives on the problems you face.
• Offers a user-friendly layout with a consistent chapter format. 1. summary boxes. 2. A full-color design. 3. And more than 1,445 illustrations (1,200 in full color), to make reference easy and efficient.

The Molecular Basis of Cancer by John Mendelsohn, Peter Howley, Mark Israel, Joe Gray, and Craig Thompson Hardcover - 704 pages Shipped in CLICK HERE Cat.# EL-ONC8 $192.70 BUY Published:  2008   ISBN:  9781416037033

Successfully fighting cancer starts with understanding how it begins. This thoroughly revised 3rd Edition explores the scientific basis for our current understanding of malignant transformation and the pathogenesis and treatment of cancer. A team of leading experts thoroughly explain the molecular biologic principles that underlie the diagnostic tests and therapeutic interventions now being used in clinical trials and practice. Incorporating cutting-edge advances and the newest research, the book provides thorough descriptions of everything from molecular abnormalities in common cancers to new approaches for cancer therapy. A new full-color format expedites reference, and now as an Expert Consult title, it enables you to conveniently search the entire text online, download all of the book’s images for your personal use, and review periodic updates.

• Offers online access the book's complete contents - fully searchable - along with periodic updates, and artwork from the text for your personal use.
• Features sweeping updates throughout, including molecular targets for the development of anti-cancer drugs, gene therapy, and vaccines...keeping you on the cutting edge of your specialty.
• Offers a new, more user-friendly full-color format so the information that you need is easier to find.
• Presents abundant figures - all redrawn in full color - illustrating major concepts for easier comprehension.

Prostate Cancer by May Abdel-Wahab, and Orlando E. Silva  Softcover - 336 pages Shipped in CLICK HERE Cat.# EL-ONC9 $ 82.70 BUY Published:  2008   ISBN:  9780702028908

This handbook is written to provide a “bedside” reference for the practicing oncologist, as well as a compendium of prostate cancer information useful to urologists, clinical researchers and educators, medical students and nurses. The book is written in outline format to provide the reader with quick and easy access to information on the major trials, landmark articles, and reviews in prostate cancer. The results of important clinical trials are summarised in 5-10 lines, with key data including : whether or not randomised, number of subjects, study periods, median follow-up, dosages, results, limitations and conclusions. In addition, there is a comprehensive index so that specific information can be found quickly.

• Practical “bedside” guide for the busy oncologist and urologist.
• Includes summaries of landmark articles and reviews that have changed clinical practice.
• Quick and easy access to the latest information on all aspects of prostate cancer clinical practice and management.

Benign prostatic disease. History of prostate cancer. Epidemiology. Risk factors. Screening. Imaging studies. Evaluation of an enlarged prostate gland and/or rising PSA. Prostate pathology. Staging. Management of prostate intra-epithelial neoplasia (PIN). Clinically insignificant prostate cancer. External beam radiation therapy. Pelvic lymph node irradiation. Brachytherapy. Prostatectomy. Post prostatectomy radiotherapy. Primary hormonal therapy. Cryosurgery. Endocrine therapy for localised disease. Prostate recurrence. Metastatic prostate cancer. Endocrine therapy for metastatic prostate cancer. Chemotherapy for prostate cancer. Side effects of treatment. Investigational agents. Following prostate cancer patients. Unusual prostatic neoplasms. Chemoprevention.

Intensive research over the last fifteen years has yielded a vast expansion in our understanding of the role of inheritance and genetics in a variety of cancers. Several inherited conditions have been identified which result in a high risk of various cancers; some of these were previously recognized, but the genetic basis underlying them has now been elucidated. This knowledge is now entering the sphere of routine clinical care. Once the preserve of researchers and highly specialized units, genetic testing for cancer predisposition is now accessible to most clinicians via regional genetics units; in the USA patients can access commercial genetic testing facilities. There is a growing evidence base to guide family screening and clinical management of affected individuals.

Surgeons, gastroenterologists, gynaecologists, oncologists, endocrinologists and many others need an awareness of these disorders, an understanding of genetic testing and when it is indicated, and how to manage patients with inherited cancer predisposition and their families. Testing for these conditions has potential legal, ethical and financial implications different from those which most clinicians regularly encounter, and continuing scientific and clinical advance means that patients and their doctors will face regular changes in management.

This book covers the basic concepts of cancer genetics. The common inherited cancer syndromes are each dealt with in greater depth, with the current management outlined. This book is aimed at all clinicians who may encounter these conditions in their practice. It aims to facilitate identification of high-risk individuals and families, to inform interaction with geneticists and other sub-specialists, to provide a basis for patient management and to stimulate interest in these fascinating conditions.

A Practical Guide to Lung Cancer by Luis Raez, and Orlando Silva Softcover - 272 pages Shipped in CLICK HERE Cat.# EL-ONC11 $ 82.70 BUY Published:  2008   ISBN:  9780702028892

This handbook is written to provide a 'bedside' reference for the practising oncologist, as well as a compendium of lung cancer information useful to thoracic surgeons, pulmonologists, respiratory medicine specialists, clinical researchers and educators, medical students and nurses. The book is written in outline format to provide the reader with quick and easy access to information on the major trials, landmark articles and reviews in lung cancer. The results of important clinical trials are summarised in 5-10 lines, with key data including: whether or not randomised; number of subjects; study periods; median follow-up; dosages; results; limitations and conclusions. In addition, there is a comprehensive index so that specific information can be quickly found.

• Practical 'bedside' guide for the busy oncologist.
• Includes summaries of landmark articles and reviews that have changed clinical practice.
• Quick and easy access to the latest information on all aspects of lung cancer, clinical practice and management.

History of lung cancer. Epidemiology of lung cancer. Screening for lung cancer. Imaging in lung cancer. Diagnostic techniques in lung cancer. Lung pathology. Surgery in non-small-cell lung cancer. Neoadjuvant therapy for non-small-cell lung cancer . Adjuvant chemotherapy for non-small-cell lung cancer. Combined modality therapy for locally advanced non-small-cell lung cancer. Chemotherapy in advanced non-small-cell lung cancer. Surgery in small-cell lung cancer. Chemotherapy in limited-disease, small-cell lung cancer. Radiation therapy for limited-disease, small-cell lung cancer. Extensive-disease, small-cell lung cancer. Malignant mesothelioma. Lung cancer in the elderly population and poor performance status. Targeted therapy in non-small-cell lung cancer. Vaccine therapy in lung cancer. Palliative treatment in lung cancer. Lung cancer in women.

The Cancer Clock by Sotiris Missailidis Hardcover - 320 pages Shipped in CLICK HERE Cat.# JW-ONC21 $158.20 BUY Published:  2007   ISBN:  9780470061510

The Cancer Clock is a comprehensive overview of cancer as a single topic and provides an all-encompassing account of the key aspects related to the disease from its causes and initial diagnosis through to treatment and care and the different support mechanisms available. Carefully divided into three key parts, the first part of the book focuses on the genesis of the disease through environmental, lifestyle and socioeconomic factors. The second part moves on to consider early disease, disease development, diagnosis, monitoring and imaging of the disease. The book then discusses standard treatments such as surgery, chemotherapy, radiotherapy and immunotherapy along with current developments in the field such as targeted therapeutics, antibody therapies and novel chemotherapy agents. The book closes with a discussion of patient care, pain control, nursing in cancer patients and rehabilitation processes and a final chapter that looks at the psychological and psychosocial aspects of the disease, from coping with the knowledge of having cancer to coping with the side effects of the treatments, family support and dedicated support groups.

Written in a clear, accessible manner this book is an ideal starting point for students of pharmacy, pharmacology, the biomedical sciences and other related disciplines where an understanding of cancer as a whole is required.

• takes an interdisciplinary approach covering the chemistry, epidemiology, basic biology and genetics, radiology, medical physics, medicine, nursing, health and social welfare all associated with cancer diagnosis, treatment and care.
• explains the various causes of cancer and suggests actions for the prevention of the disease.
• includes chapters on current diagnostic tests, drug development and the techniques used in drug design both chemical and biological.
• considers current experimental therapeutic and diagnostic approaches and their potential for future therapeutic development.
• examines aspects of cancer care, physiotherapy, rehabilitation and the psychological aspects of the disease
• includes self assessment questions/answers, summary sections and review questions and information boxes to enhance student understanding.

Table of Contents:

Preface
List of Contributors

1. Socioeconomic and molecular basis of cancer

1.1 Introduction
1.2 Diet and cancer
1.3 Alcohol and cancer
1.4 Tobacco and cancer
1.5 Conclusions
1.6 Self-assessment questions
1.7 Further reading and resources

2. Metal ions and Cancer

2.1 Introduction
2.2 Metal–DNA interactions
2.3 Uranium–nucleotide interaction
2.4 Toxicity and biological roles of copper
2.5 Formation of free radicals by metal ions
2.6 Radiolysis
2.7 Biomolecular targets of free radicals
2.8 Free radicals and metal ions in cancer
2.9 Conclusions
2.10 Self-assessment questions
2.11 Further reading and resources

3. Genetics and cancer

3.1 Introduction
3.2 Genes and cancer
3.3 Genomics
3.3.1 Comparative genomics
3.3.2 Oncogenomics
3.3.3 Nutrigenomics
3.4 Summary
3.5 Self-assessment questions
3.6 Further reading and resources

4. Infection and cancer

4.1 Viral infection as a cause of cancer
4.1.1 Introduction
4.1.2 Principles of oncogenic transformation by virus infection
4.1.3 Human pathogenic viruses causing cancer
4.2 Bacterial infection as a cause of cancer
4.2.1 Introduction
4.2.2 Bacterial infection causing malignancies: examples and evidence
4.2.3 Common molecular machines linked to pathogenesis: Type 3 and 4 secretion systems
4.2.4 Other bacterial effects potentially contributing to cancer
4.2.5 Anti-infection strategies to prevent infection related cancer
4.3 Summary
4.4 Self-assessment questions
4.5 Further reading and resources

5. Inflammation and cancer

5.1 Introduction
5.1.1 Acute inflammation
5.1.2 Chronic inflammation
5.2 Acute inflammation
5.2.1 Mediators of acute inflammation
5.3 Chronic inflammation
5.4 Drugs used in inflammation and cancer
5.4.1 COX-2 inhibitors
5.4.2 Antihypertensive drugs
5.5 Evidence for a molecular link between inflammation and cancer
5.6 Clinical relationship between inflammatory disease and cancer
5.6.1 Inflammatory bowel disease
5.6.2 Prostate cancer
5.7 Discussion
5.8 Self-assessment questions
5.9 Further reading and resources

6. Cancer diagnosis

6.1 Blood tests for tumour markers
6.1.1 Established and novel tumour markers in serum
6.1.2 Various types of tumour markers in use
6.2 Urine tests for tumour markers
6.3 Smear tests and their association with tumour development
6.4 Histopathology
6.4.1 Benign tumours
6.4.2 Malignant tumours
6.4.3 Features of cancerous cells
6.4.4 Immunohistochemistry
6.5 Summary
6.6 Self-assessment questions
6.7 Further reading and resources

7. Tumour imaging and therapy

7.1 Introduction
7.2 X-ray imaging
7.2.1 Mammography
7.2.2 X-ray CT
7.3 Nuclear medicine
7.3.1 The gamma camera
7.3.2 Positron emission tomography
7.3.3 Intra-operative probes
7.4 Ultrasound imaging
7.4.1 Colour doppler imaging
7.5 Magnetic resonance imaging
7.6 Radiation therapy
7.6.1 Therapeutic nuclear medicine
7.6.2 Brachytherapy
7.6.3 External beam radiotherapy
7.7 Conclusions
7.8 Acknowledgement
7.9 Self-assessment questions
7.10 Further reading and resources

8. Surgery

8.1 Introduction
8.1.1 What is surgery?
8.1.2 What is cancer surgery?
8.1.3 Who deals with cancer surgery?
8.1.4 Aims of cancer surgery
8.2 Cancer surgery as a diagnostic procedure
8.3 Cancer surgery as a preventive method against cancer
8.4 Cancer surgery as a treatment or part of the treatment
8.4.1 Surgery as a primary treatment
8.4.2 Cancer staging
8.4.3 Debulking (cytoreductive) surgery
8.4.4 Palliative surgery (relieving symptoms or side effects)
8.5 Classic/traditional cancer surgery
8.6 Other common techniques in cancer surgery
8.6.1 Electrosurgery
8.6.2 Cryosurgery
8.6.3 Laser surgery and photo dynamic therapy (PDT)
8.6.4 Mohs’ micrographic surgery
8.6.5 Laparoscopic surgery
8.6.6 Image-guided surgery
8.7 Before and after cancer surgery
8.7.1 Preparation for the surgery
8.7.2 Anaesthesia
8.7.3 Recovery
8.8 Cancer surgery associated risks
8.9 Informed consent
8.10 Summary
8.11 Self-assessment questions
8.12 Further reading and resources

9. Anticancer therapeutics

9.1 Introduction
9.1.1 Problems in cancer
9.1.2 Cancer treatments
9.1.3 Classification of chemotherapy drugs
9.2 Platinum drugs
9.2.1 Cisplatin
9.2.2 LipoplatinTM
9.2.3 Carboplatin
9.2.4 Oxaliplatin
9.2.5 New platinum compounds
9.3 Antimicrotubule agents
9.3.1 Taxanes
9.3.2 Vinca alkaloids
9.4 Antimetabolites
9.4.1 5-Fluorouracil
9.4.2 Xeloda (capecitabine)
9.4.3 Structure of gemcitabine
9.5 Antitumour antibiotics
9.5.1 Actinomycin D
9.5.2 Mitomycin C
9.5.3 Bleomycin
9.5.4 Anthracyclines
9.5.5 Podophyllotoxins
9.5.6 Camptothecins
9.6 Alkylating agents
9.6.1 Cyclophosphamide
9.6.2 Ifosfamide
9.6.3 Temozolomide (Temodal)
9.7 Other antitumour agents
9.7.1 Tamoxifen
9.8 Combination chemotherapy
9.9 Growth factor signalling
9.9.1 Tarceva
9.9.2 Other signal transduction inhibitors
9.10 Cell cycling and cancer
9.11 Apoptosis and cancer
9.12 Angiogenesis and cancer
9.13 Cancer immunotherapy
9.13.1 Monoclonal antibodies as anticancer drugs
9.13.2 Cancer vaccines
9.14 Gene therapy
9.15 RNAi (siRNA)
9.16 Antisense
9.17 Viruses able to kill cancer cells
9.18 Aptamers
9.19 Summary
9.20 Self-assessment questions
9.21 Further reading and resources

10. Palliative care in oncology

10.1 Palliative care: concept and brief history
10.2 Cancer epidemiology and palliative care around the world
10.3 Bioethics and palliative care
10.4 Basic principles in palliative care
10.5 Symptom control in oncology palliative care
10.5.1 Pain relief in cancer
10.6 Advanced cancer: related symptoms and interventions
10.6.1 Fatigue
10.6.2 Dyspnoea
10.6.3 Cognitive aspects
10.6.4 Constipation
10.6.5 Anorexia
10.6.6 Nausea and vomiting
10.6.7 Ulcerated lesions
10.7 Psycho-spiritual aspects in oncology palliative care
10.8 Conclusion
10.9 Self-assessment questions
10.10 Further reading and resources

11. Physiotherapy in cancer patients

11.1 Physiotherapy and oncology
11.2 The importance of studies about cancer and physiotherapy
11.3 Possible interventions of the physiotherapist in specific types of cancer
11.3.1 Breast cancer
11.3.2 Gynaecological cancers
11.3.3 Prostate cancer
11.3.4 Head and neck cancers
11.3.5 Melanoma and non-melanocytic skin cancers
11.3.6 Colorectal cancer
11.3.7 Lung cancer
11.3.8 Non-Hodgkin’s lymphoma
11.4 Physiotherapy, exercise prescription and technology advances
11.5 Physiotherapy and palliative care in oncology
11.6 Physiotherapy in the actions, community expectations and quality of life in oncology
11.7 Self-assessment questions
11.8 Further reading and resources

12. Psychosocial oncology

12.1 Introduction
12.2 Cancer and psychological distress
12.3 Assessment process
12.3.1 Integrating sources of information
12.3.2 Using diaries for assessment
12.4 Formulation
12.5 Psychological interventions
12.5.1 Processes targeted in psychological interventions
12.5.2 Specific treatment modalities
12.6 Does psychological intervention influence survival?
12.7 Summary
12.8 Self-assessment questions
12.9 Further reading and resources

Index

Acute Leukemias by Elihu H. Estey, Stefan H. Faderl, and Hagop Kantarjian Hardcover - 308 pages Shipped in CLICK HERE Cat.# DA-ONC18 $175.40 BUY Published:  2007   ISBN:  9783540723028

• Massive practical value as clinicians are brought up to date on most recent advances in acute leukemia treatment
• Authors delineate the development of new therapies
• Lays out the current state of knowledge on the subject
• Examines new classification systems that have been coming on stream

It is one of the most crucial areas of exploration in medicine today – and here is an important addition to the literature on the subject.

As research into cancers progresses, scientists are becoming ever more aware that better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells.

This hugely important new book describes the current knowledge of acute leukemia biology and discusses new classification systems that have arisen as a result of emerging insights into pathogenesis.

Estey, Faderl and Kantarjian, who all work at the respected Anderson Cancer Center in Houston, Texas, USA, examine in detail advances in the treatment of particular types of acute leukemia. Their book also covers the management of acute leukemia in general as well as the development of new therapies.

Table of Contents:
Acute Myeloid Leukemia: Epidemiology and Etiology. Diagnosis and Classification of the Acute Myeloid
Leukemia. Therapy of Acute Myeloid Leukemia. Acute Lymphoblastic Leukemia: Epidemiology and Etiology. Relapsed and Refractory Acute Myeloid Leukemia. Molecular Biology and Genetics. Clinical Presentation, Diagnosis, and Classification. Diagnosis of Acute Lymphoblastic Leukemia. Recent Clinical Trials in Acute Lymphoblastic Leukemia by the Cancer and Leukemia Group B. General Approach to the Therapy of Adult Acute Lymphoblastic Leukemia. Conventional Therapy in Adult Acute Lymphoblastic Leukemia: Review of the LALA Program. Acute Lymphoblastic Leukemia Therapy: Review of the MD Anderson Program. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Burkitt's Acute
Lymphoblastic Leukemia (L3ALL) in Adults. The Role of Allogeneic Stem Cell Transplantation in the Therapy of Adult Acute Lymphoblastic Leukemia. The Role of Allogeneic Stem Cell Transplantation in the Therapy of Adult Acute Lymphoblastic Leukemia. The Role of Allogeneic Stem Cell Transplantation in the Therapy of Adult Acute Lymphoblastic Leukemia. Novel Therapies in Acute Lymphoblastic Leukemia. Minimal Residual Disease Studies in Acute Lymphoblastic Leukemia. Central Nervous System Involvement in Adult Acute Lymphocytic Leukemia. Relapsed Acute Lymphoblastic Leukemia. Emergencies in Acute Lymphoblastic Leukemia.

Percutaneous Tumor Ablation in Medical Radiology by Thomas J. Vogl, Thomas Helmberger, Martin G. Mack, and Maximilian F. Reiser Hardcover - 432 pages Shipped in CLICK HERE Cat.# DA-ONC19 $247.25 BUY Published:  2007   ISBN:  9783540225188

• Clearly explains the basics of thermal ablative techniques
• Discusses in detail the techniques employed to guide applicators to the target structures using different imaging tools
• Presents results achieved in a variety of clinical conditions
• Benefits from numerous excellent images
• Written by a large number of acknowledged experts

Thermal ablation has become an integral part of oncology, especially in the field of interventional oncology. This very comprehensive book encompasses the different technologies employed in thermal ablation, its indications and the results achieved in various clinical conditions. The first part of the book clearly explains the basics of thermal ablative techniques such as laser-induced thermotherapy, radiofrequency ablation, microwave ablation, cryotherapy, and localized tumor therapy. The latest developments in the application of minimally invasive therapies in localized neoplastic disease are demonstrated. In the main part of the book, techniques of guiding the applicators to the target structures by use of different imaging tools such as ultrasound, computed tomography and magnetic resonance imaging are discussed. The results are presented for a variety of clinical indications, including liver and lung tumors and metastases and some rather rare conditions involving the kidney, the head and neck, the prostate, and soft tissue structures. A large number of acknowledged experts have contributed to the book, which benefits from a lucid structure and excellent images.

Contents:
Basic Principles in Oncology. Ablative Techniques: Thermal Ablative Techniques. Radiofrequency Ablation. Microwave Ablation. Laser Ablation. Cryoablation. Vascular Ablative Techniques: Locoregional Chemotherapy incl. Perfusion. Chemoembolization. Actinic Ablative Techniques: Percutaneous Brachytherapy. Selective Internal RadiationTherapy. Iodine 131 Embolization. Instillation Techniques: Instillation of Alcohol. Instillation of Bone Cement. Clinical Indications Liver: Primary Tumors: TACE (and Combinations). PAI. RFA. LITT. Secondary Tumors: RFA. LITT. Benign Tumors (Symptomatic Hemangiomas, Adenomas): Embolization. RFA. Kidney: Embolization. RFA. Cryo. Lung: RFA. LITT. Soft Tissue and Musculoskeletal: RFA. LITT. Other: Head and Neck. Breast. Treatment Strategies: HCC. Bone Tumors. Vendor Lists and Helpful Data: Vendors for IR Equipment. Dosage Tables. www Links to Helpful Sites. Subject Index. List of Contributors.

Surgery of Spinal Tumours by Jörg Klekamp, and Madjid Samii Hardcover - 640 pages Shipped in CLICK HERE Cat.# DA-ONC1 $533.60 BUY Published:  2007   ISBN:  9783540447146

This comprehensive monograph describes the experience gained through the treatment of patients with spinal tumors over a 25-year period. It covers clinical presentations and neuroradiological features of intramedullary, extramedullary and extradural spinal tumors. Furthermore, it provides step-by-step intraoperative photographs to describe surgical strategies and techniques, and gives detailed statistical analyses on postoperative outcomes by focussing on postoperative complications as well as short-term and long-term results. A reliable reference, this book will be of great interest to neurosurgeons, neurologists, neuroradiologists, neuromolecular biologists, neurophysiotherapists and occupational therapists.

• Authoritative reference covering all tumor entities of the spine and spinal cord
• Step-by-step illustrations of surgical procedures
• Detailed statistical evaluations for every tumor pathology
• Abundantly illustrated with 1862 figures

Cancer Clinical Trials, Proactive Strategies by Stanley P.L. Leong Hardcover - 318 pages Shipped in CLICK HERE Cat.# DA-ONC2 $192.70 BUY Published:  2007   ISBN:  9780387332246

Clinical trials remain the most important vehicle for improving the care of cancer patients. This text presents the fundamental components and challenges involving clinical investigations. Leading experts discuss the critical issues covering the spectrum of important topics from
planning to application.

Contents:
Preface - Foreword - Historical Perspective and Evolving Concerns for Human Research - Cancer Trials and the Institutional Review Board (IRB) - NCI's Cancer Therapy Evaluation Program: A Commitment to Treatment Trials - The Role of FDA in Cancer Clinical Trials - The Role of Cooperative Groups in Cancer Clinical Trials - The Advocate Role in Clinical Study Development and Partnering with Patient
Advocates in Your Local Institution - The National Breast Cancer Coalition: Setting the Standard for Advocate Collaboration in Clinical Trials - The Role and Responsibility of the Principal Investigator in Cancer Clinical Trials - The Audit Process and How to Ensure a Successful Audit - The Privacy Rule (HIPAA) As It Relates To Clinical Research - The Commission on Cancer, American College of Surgeons' Response to HIPAA - Ethical and Legal in the Conduct of Cancer Clinical Trials - The Role of the Office of Research Integrity in Cancer Clinical Trials - Strategies for the Administration of a Clinical Trials Infrastructure: Lessons from a Comprehensive Cancer Center - The Clinical Research Process: Building a System in Harmony with its Users - Cancer Research and Clinical Trial in Action: An Important Exercise Before You Embark - Conclusion - Index.

Pediatric Lymphomas by Howard Weinstein, Melissa Hudson and Michael Link Hardcover - 228 pages Shipped in CLICK HERE Cat.# DA-ONC3 $192.70 BUY Published:  2007   ISBN:  9783540203568

The book covers the epidemiology, pathology, molecular biology, clinical features, diagnosis, and
treatment of Hodgkin and non-Hodgkin lymphomas in children and adolescents. It is a combined
effort of investigators who are leaders in the field of childhood lymphomas. Introductory chapters on Hodgkin and non-Hodgkin lymphomas in children provide a concise historical overview. All chapters have a standalone structure and those regarding the individual subtypes of lymphomas provide up-to-date results of recent clinical trials and practical guidelines for work-up and treatment. The pathology chapters are comprehensive and include excellent photographs as well as detailed review of the scientific advances pertaining to the molecular pathogenesis of each type of malignant lymphoma seen in childhood. There is also a concise chapter on post-transplant lymphoproliferative disease and lymphomas associated with congenital and acquired immunodeficiency states. The book is at the level of subspecialists in pediatric hematology and oncology, radiation oncology, pediatric surgery and hematopathology.

Table of Contents
Hodgkin's Diseases: Introduction/ Historical Background - Biology, Pathology - Lymphocyte Predominant Hodgkin's Disease - Treatment of Pediatric Hodgkin's disease - Treatment of Relapsed/ Refractory Hodgkin's Disease. Non-Hodgkin's Lymphoma: Introduction/ Historical Background - Biology/ Pathology - B-Cell/ Burkitt's Lymphoma - Anaplastic Large Cell Lymphoma - Lymphoblastic Lymphoma -Pathology of Cutaneous and rare Non-Hodgkins's Lymphomas.- Posttransplant Lymphoproliferative Disease. Combined HD/NHL Chapters: Epidemiology/ Pathology - Large B Cell Lymphoma and Indolent B Cell Lymphomas - Late Effects after Lymphoma Treatment.

Myeloproliferative Disorders by Junia V. Melo, and John M. Goldman Hardcover - 349 pages Shipped in CLICK HERE Cat.# DA-ONC4 $241.75 BUY Published:  2007   ISBN:  9783540345053

This book contains a series of contributions from internationally renowned academics with special
expertise in one or other diseases which collectively are grouped under the heading
myeloproliferative disorders. For the editors this term includes Ph-positive chronic myeloid leukemia but also the various Ph-negative variants, some of which provide fascinating insights into the molecular mechanisms of the leukemias. There have been many recent developments in understanding the pathophysiology and a number therapeutic innovations in this area. One particular merit of this book is the speed with which it has been produced, an important factor in this very rapidly moving field.

Contents:
Story of CML.- Bcr-Abl and signal transduction - Biology of advanced phase - Clinical features - Development of signal transduction inhibitors - Treatment with tyrosine kinase inhibitors - Allografting.- Autografting - Monitoring disease response - Experimental drugs.- Immunotherapy.- Therapeutic strategies and clinical trials - Ph-negative CML -Eosinophilic leukemia - Primary myelofibrosis - Polycythemia vera - Essential thrombocythemia.

The Cutaneous Lymphoid Proliferation by Cynthia M. Magro, Neil Crowson, and Martin C. Mihm Jr. Hardcover - 499 pages Shipped in CLICK HERE Cat.# JW-ONC1 $338.20 BUY Published:  2007   ISBN:  9780471695981

A Comprehensive Textbook of Lymphocytic Infiltrates of the Skin

The Cutaneous Lymphoid Proliferation: A Comprehensive Textbook of Lymphocytic Infiltrates of the Skin provides a complete summary of the clinical features, phenotype, pathogenesis, histopathology, diagnosis, and treatment of lymphocytic infiltrates of the skin. It begins with a clinical atlas and introduction to the ontogeny and biology of the lymphoid system. The next section discusses novel molecular approaches to the diagnosis of cutaneous lymphoid proliferation and benign lymphocytic infiltrates. The remaining chapters focus on major inflammatory skin diseases and lymphoproliferative disorders, including chronic lymphocytic leukemia, lupus, adult T cell leukemia, and primary cutaneous Hodgkin’s disease.

• Provides hundreds of full colour, high-quality clinical and histologic photographs
• Integrates the biology, pathology, clinical features, diagnostic techniques, and therapeutic management of these entities
• Elucidates the role of the immune system in the pathogenesis of cutaneous disease
• Discusses the relationship between therapeutic drugs and cutaneous eruptions
• Covers drug reactions
• Reviews insights from light microscopy, immunohistochemistry, and flow cytometry
• Incorporates useful tables throughout

With its authoritative treatment of both tumour and non-tumour entities of the skin, this title is an invaluable resource for all dermatologists, dermatopathologists, oncologists, and general pathologists.

Table of Contents:

Chapter One: Introduction to the Classification of Lymphoma

Kiel, Lukes–Collins, and Working Formulation Classifications
WHO, Real, and EORTC Classifications
Summary
References
Appendix: Definitions of Key Terms and Techniques

Chapter Two: The Therapy of Cutaneous T Cell Lymphoma

Introduction
Diagnostic Work-up and Staging Procedures
Goals of Therapy in Advanced Stage CTCL
Extracorporeal Photopheresis (ECP)
Interferons
Retinoids
Immunotoxins
Monoclonal Antibodies
Cytotoxic Chemotherapy
Investigational Therapies
Monoclonal Antibodies
TLR Agonists and Cytokines
Histone Deacetylase Inhibitors (HDACi)
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
CTCL Therapies
Skin-Directed Therapies
References

Chapter Three: Molecular Techniques

Introduction
Immunoglobulin Receptor Structure
IgH
TCR-β
PCR Design for Determination of Clonality
Detection of PCR Products for Clonality
Evaluation of Results
Limitations of Clonality Assessment by PCR
Summary
References

Chapter Four: Benign Lymphocytic Infiltrates

Introduction
Spongiotic and Eczematous Dermatitis
Allergic Contact Dermatitis
Pityriasis Rosea
Pityriasis Rosea-like Drug Reaction
Other Spongiotic/Eczematous Tissue Reactions
Photoallergic Reactions
Other Causes of Subacute Eczematous Dermatitis
Nummular Eczema
Small Plaque Parapsoriasis
Pruritic Urticarial Plaques and Papules of Pregnancy
Superficial Erythema Annulare Centrifugum
Interface Dermatitis: Cell-Poor Vacuolar Interface Dermatitis
Erythema Multiforme
Gianotti–Crosti Syndrome (Popular Acrodermatitis of Childhood)
Acute Graft-Versus-Host Disease
Morbiliform Viral Exanthem and Morbiliform Drug Eruption
Collagen Vascular Disease Compatible with Antibody-Dependent Cellular Immunity and/or Anti endothelial Cell Antibodies
Interface Dermatitis: Lichenoid Pattern
Lichen Planus
Lichen Planus-like Eruptions of Hepatobiliary Disease
Lichen Planus-like Eruptions of Secondary Syphilis
Lichenoid Drug Reactions
Lichenoid Connective Tissue Disease Syndromes
Lichenoid (‘‘Chronic’’) Graft-Versus-Host Disease
Diffuse and Nodular Lymphocytic Dermal Infiltrates Without Atypia
Polymorphous Light Eruption as the Prototypic Type IV Immune Reaction
Other Dermal Perivascular Lymphocytic Infiltrates
Gyrate Erythemas
Diffuse and Nodular Lymphocytic Infiltrates Associated with Autoimmune Disease
Nonscarring Discoid Lupus Erythematosus/Tumid Lupus Erythematosus
Morphea
Jessner’s Lymphocytic Infiltrate of the Skin
References

Chapter Five: Reactive Lymphomatoid Tissue Reactions Mimicking Cutaneous T and B Cell Lymphoma

Lymphomatoid Drug Eruptions
Molecular Profile of Lymphomatoid Drug Eruptions
Pathogenetic Basis of Lymphomatoid Drug Reactions
Reactive Lymphomatoid Lesions Encountered in Lesions of Collagen Vascular Disease
Lymphomatoid Lupus Erythematosus
Pathogenesis of Lymphomatoid Tissue Response in Collagen Vascular Disease
Lupus Erythematosus Profundus
Viral-Associated Lymphomatoid Dermatitis
Lymphocytoma Cutis
Primary Cutaneous Plasmacytosis
Conclusion
Case Vignettes
References

Chapter Six: Precursor Lesions of Cutaneous T Cell Lymphoma

Cutaneous T Cell Lymphoid Dyscrasia
Large Plaque Parapsoriasis
Hypopigmented Epitheliotropic T Cell Dyscrasia/Hypopigmented Large Plaque Parapsoriasis as a Precursor Lesion to Hypopigmented Mycosis Fungoides
Pigmented Purpuric Dermatosis (PPD)
Pityriasis Lichenoides Chronica
Syringolymphoid Hyperplasia with Alopecia
Idiopathic Follicular Mucinosis/Alopecia Mucinosa
Atypical Lymphocytic Lobular Panniculitis
Case Vignettes
Additional Molecular and Cytogenetic Studies
References

Chapter Seven: Marginal Zone Lymphoma and Other Low-Grade B Cell Lymphoproliferative Disorders of the Skin

Marginal Zone Lymphoma
Castleman’s Disease
Primary Cutaneous Plasmacytoma
Case Vignettes
References

Chapter Eight: Primary Cutaneous Follicle Center Cell Lymphoma

Case Vignettes
Additional Molecular and Cytogenetic Study
References

Chapter Nine: Primary Cutaneous Diffuse Large B-Cell Lymphoma and Precursor Lymphoblastic Lymphoma

Primary Cutaneous Diffuse Large B-Cell Lymphoma
Cutaneous Precursor B Cell Lymphoblastic Lymphoma/Lymphoblastic Leukemia (Precursor B Cell Acute Lymphoblastic Leukemia
Case Vignettes
Additional Molecular and Cytogenetic Studies
References

Chapter Ten: Intravascular Lymphoma

Case Vignette
References

Chapter Eleven: Chronic Lymphocytic Leukemia of B Cell and T Cell Phenotype (T Cell Prolymphocytic Leukemia)

B Cell Chronic Lymphocytic Leukemia
T Cell Prolymphocytic Leukemia
Case Vignettes
Additional Molecular and Cytogenetic Studies
References

Chapter Twelve: Cutaneous Mantle Cell Lymphoma

Case Vignettes
Additional Molecular and Cytogenetic Studies
References

Chapter Thirteen: Primary Cutaneous γ δ T Cell Lymphoma

Introduction
Case Vignette
References

Chapter Fourteen: Mycosis Fungoides

Definition
Historical Perspective
Demographics
Clinical Presentation
Patch Stage
Plaque Stage
Tumor Stage
Extracutaneous Dissemination
Clinical Variants
Papuloerythroderma
Mycosis Fungoides in Childhood
Adnexotropic Mycosis Fungoides
Woringer–Kolopp Disease (Pagetoid Reticulosis)
Granulomatous Slack Skin/Granulomatous Mycosis Fungoides
Sezary Syndrome
Extracutaneous Involvement in Mycosis Fungoides
Phenotypic Profile
Molecular Profile
Cytogenetics
Pathogenesis
Case Vignettes
Additional Molecular and Cytogenetic Studies
References, 297

Chapter Fifteen: Primary Cutaneous Pleomorphic Small/Medium Sized T-Cell Lymphoma And Peripheral

T-Cell Lymphoma, Unspecified, Presenting in the SKIN (CD30-Negative Large Cell T Cell Lymphoma) Case Vignettes
Additional Molecular and Cytogenetic Study
References

Chapter Sixteen: Adult T Cell Leukemia/Lymphoma

Case Vignettes
References

Chapter Seventeen: Angioimmunoblastic Lymphadenopathy (AILD)/Angioimmunoblastic T Cell Lymphoma

Case Vignettes
References

Chapter Eighteen: CD8 T Cell Lymphoproliferative Disease of the Skin

Introduction
Primary Cutaneous CD8 Lymphoma
CD8 Variant of Lymphomatoid Papulosis and Other Related CD30-Positive T Cell Lymphoproliferative Disorders of CD8 Subtype
CD8 Prolymphocytic Leukemia
CD8 Pseudolymphoma Related to Underlying HIV Disease
CD8 Cytotoxic Pseudolymphoma Related to Drug Therapy
Case Vignettes
References

Chapter Nineteen: Subcutaneous Panniculitis-Like T Cell Lymphoma

Case Vignettes
References

Chapter Twenty: Epstein–Barr Virus-Associated Lymphoproliferative Disease

Introduction
Hydroa Vacciniforme-Like EBV-Associated T Cell Lymphoproliferative Disease/Mosquito Bite Hypersensitivity
Epstein–Barr Virus-Associated B Cell Lymphoproliferative Disease in the Setting of Iatrogenic Immune Dysregulation
Case Vignettes
References

Chapter Twenty-One: Nasal and Related Extranodal Natural Killer Cell/T Cell Lymphomas

Introduction
Biology of NK and NK-like T Cells
NK/T-Cell Lymphoma
Nasal NK/T-Cell Lymphoma
Nasal Type NK/T Cell Lymphoma
Aggressive NK Cell Lymphoma
Role of Epstein–Barr Virus in the Evolution of NK/T Cell Lymphomas
Blastic/Blastoid NK Cell Lymphoma/Agranular CD4-positive CD56-positive Hematodermic Neoplasm
Panniculitis-like T Cell Lymphoma Showing CD56 Positivity
Chronic Granular Lymphocytosis/Large Granular Cell Leukemia
Natural Killer-like T Cell Lymphoma of the CD4 Subset: A Rare Variant of Natural Killer Cell Lymphoma to Be Distinguished from the Hematodermic Neoplasm
Case Vignettes
References

Chapter Twenty-Two: Lymphomatoid Granulomatosis (LYG)

Introduction
Case Vignette
References

Chapter Twenty-Three: CD30-Positive Lymphoproliferative Disorders Including Lymphomatoid Papulosis, Borderline CD30-Positive Lymphoproliferative Disease, Anaplastic Large Cell Lymphoma, and T-Cell-Rich CD30-Positive Large B Cell Lymphoma

Introduction
Lymphomatoid Papulosis
CD8 Lymphomatoid Papulosis
Borderline CD30-Positive Lymphoproliferative Disorders (Type C LYP) (Case Vignette 9)
Cutaneous Anaplastic Large Cell Lymphoma
CD30-Positive Large B Cell Lymphoma
Case Vignettes
Additional Molecular and Cytogenetic Studies
References

Chapter Twenty-Four: Primary Cutaneous Hodgkin Lymphoma

Subtypes of Hodgkin Lymphoma
Classic Hodgkin Lymphoma
Lymphocyte-Predominant Hodgkin lymphoma
Case Vignette
Additional Molecular and Cytogenetic Studies

References
Index

Invasive Bladder Cancer by Pierfrancesco Bassi, and Francesco Pagano Hardcover - 340 pages Shipped in CLICK HERE Cat.# DA-ONC5 $165.40 BUY Published:  2007   ISBN:  9781846283765

There are two main types of bladder cancer: superficial and invasive. The former is four times more prevalent than the latter. Superficial bladder cancers do not invade the muscle wall while invasive tumors do. Invasive bladder tumors have a propensity to metastasize and spread to other areas of the body and are more likely to be fatal than superficial tumors.

• Updated, simple overview bridging the information coming from basic research to clinical practice
• Text uses images by Frank Netter, MD, from the Atlas of Human Anatomy, 2nd ed., c1997 and the 13-volume Netter
• Collection of Medical Illustrations.

Invasive Bladder Cancer presents state-of-the-art diagnoses and treatments available for bladder cancer that has metastasised into the body in a full color book with over 40 tables and 50 illustrations. It gives a comprehensive review of the subject by a distinguished international team covering epidemiology, screening, diagnostic factors, surgery, chemotherapy and post-operative monitoring. As this type of cancer is on the increase it will be of particular interest to office urologists, and oncologists with a specialist interest in urology.

Contents:
Epidemiology and prevention of bladder cancer. Early diagnosis and screening. Non-invasive diagnosis. Molecular pathology of tumour progression and metastasis: an introduction. Staging: past, present and future. MR imaging of the male pelvis. Invasive bladder cancer: prognostic factors. Surgical management of muscle-invasive bladder cancer. Transurethral resection in patients with muscle-infiltrating bladder cancer. Nodal involvement. Pre-operative and definitive radiation therapy in bladder cancer. Invasive bladder cancer: neo-adjuvant and adjuvant chemotherapy: true and false. Oncological rationale for function-sparing surgery - Combination therapy and function-sparing surgery for muscle-invasive bladder cancer. Metastatic transitional cell cancer: the state of the art. Invasive transitional cell cancer in the elderly. Quality of life in patients with muscle-invasive bladder cancer. Urethra involvement and bladder cancer. Lower urinary tract reconstruction in patients with bladder cancer. Salvage cystectomy.

Advances in Peritoneal Surface Oncology by Santiago González-Moreno Hardcover - 176 pages Shipped in CLICK HERE Cat.# DA-ONC6 $147.25 BUY Published:  2007   ISBN:  9783540307594

Malignant peritoneal disease in its various forms is a devastating condition for patients who suffer from it and it poses a significant challenge for the clinicians taking care of them. Research efforts in this field have traditionally been scarce under the assumption of a uniformly fatal and hopeless outcome.

In the last few decades a renewed interest in peritoneal carcinomatosis and primary peritoneal malignancies has occurred. Unprecedented favourable results reported with the employment of aggressive cytoreductive surgery combined with perioperative intraperitoneal chemotherapy have catalysed a change in the conception and treatment alternatives for these diseases. Selected patients can now be offered a curative-intent combination therapy, whereas in the past only the best possible palliation could be considered.

This book is a comprehensive compilation of the new knowledge in peritoneal surface oncology in the dawn of the twenty-first century. It covers the complete spectrum of the latest research carried out in peritoneal malignant dissemination, from its pathogenesis and molecular mechanisms to the latest clinical trials. Additionally, the essentials of perioperative intraperitoneal chemotherapy and the modern histopathological assessment of peritoneal surface malignancy are reviewed. A unique historical perspective on how this new knowledge has unfolded over the years helps point out the future research directions to be pursued. Leading experts in this field from around the world, including the pioneers who gave birth to this new era in oncology, form an unbeatable and outstanding panel of authors.

Contents:
Management of peritoneal surface malignancy. The natural history of free cancer cells in the peritoneal cavity. Pathological evaluation and implications of serosal involvement in gastro-intestinal cancer. Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy. Hyperthermic intraoperative intraperitoneal chemotherapy – a survey of techniques. Adjuvant intraperitoneal chemotherapy. Clinical research methodology in peritoneal surface oncology. Clinical trials in peritoneal surface oncology: colorectal carcinomatosis. Experimental models and questions in basic science research for pseudomyxoma peritonei. Peritoneal carcinomatosis of colorectal origin. Malignant peritoneal mesothelioma. Advances in clinical research and management of diffuse peritoneal mesothelioma. Advances in the management of gastric cancer with peritoneal dissemination. Intraperitoneal chemotherapy in the management of ovarian cancer.

Handbook of Cancer Survivorship Edited by Michael Feuerstein Hardcover - 496 pages Shipped in CLICK HERE Cat.# DA-ONC7 $124.50 BUY Published:  2007   ISBN:  9780387345611

Not long ago, a cancer diagnosis was regarded as an automatic death sentence; today there are ten
million survivors. Equally impressive is the growing number of clinicians and researchers dedicated to improving the quality of survivors' lives and care. Yet despite this encouraging picture, there has never been a reliable central source for relevant clinical information, till now.

The Handbook on Cancer Survivorship responds to the diverse needs of survivors and their support communities by comprehensively addressing the major issues in the field, from the burden of survivorship to secondary prevention. Editor Michael Feuerstein, himself a cancer survivor, and sixty other top scientist-practitioners analyze in depth how survivors meet and manage the challenges of life after cancer, and what clinicians, researchers, and public health systems can do to ease the transition.

The Handbook's 27 comprehensive chapters include the latest research and practice related to:

• Survivors' quality of life, and how it can be assessed;
• Managing everyday and chronic stress;
• Depression, anxiety, pain disorders, and cognitive changes
• Coping, adaptation, and resilience; Behavior change strategies exercise, weight control,
  smoking cessation;
• Survivor, clinician, and international perspectives;
• New frontiers in practice, research, and policy.
• Such wide-ranging coverage benefits everyone involved in cancer survival: primary care
  providers, oncologists; behavioral health specialists; physical and occupational therapists;
  nutritionists; epidemiologists; health systems professionals and policymakers; and, of course,
  survivors themselves and their families.

Contents:

Acknowledgements. Forward.

Part I. Burden. Cancer Survivorship: A Birds Eye View from an Insider. Burden of Cancer Survivorship: A Pandemic of Treatment Success. Quality of Care. Quality of Life in Long Term Survivors. Health Disparities. Measuring Health Related Quality of Life.

Part II. Mechanisms of Common Problems. Exercise Motivation and Behavior Change. Fatigue. Pain Disorders. Stress. Depression. Interpersonal Relationships. Adaptation in the Face of Advanced Cancer.

Part III. Secondary Prevention. Restoring Emotional Well-being: A Model. Physical Activity: Potential Benefits and Guidelines. Nutrition/Weight Management. Cognitive Changes. Smoking Cessation. Psychological Distress, Depression, and Anxiety. Managing Daily and Long Term Stress. Pain and Function: A Psychosocial Perspective. Work. Comprehensive Long-Term Follow-Up: Cancer Survivorship Centers.

Part IV. Survivor and Provider Perspectives. Quality Care. Living with Advanced Cancer.

Part V. International Perspective. International Approaches.

Part VI. Future Directions. Cancer Survivorship: Research, Practice and Policy The Challenges.

Index. Appendix. Worldwide sources of support for program development and research related to cancer survivorship.

Cancer Survivorship Edited by Patricia A. Ganz Softcover - 310 pages Shipped in CLICK HERE Cat.# DA-ONC8 $122.70 BUY Published:  2007   ISBN:  9780387343495

There are now 8-10 million cancer survivors in the United States alone (up from 3 million in 1971). Multiple studies have shown that most survivors today were diagnosed more than 20 years ago. As this former patient population ages, the relationships between secondary malignancies, age-related onset of certain malignancies, and screening and prevention become increasingly important, not only to the patient population, but also to the cancer management team treating the patients.

There are multiple resources available to serve as oncology textbooks, but nothing to provide the
necessary information on patient care for the non-MD members of the cancer patient management team. Cancer Survivorship provides the necessary information about not only the clinical aspects of caring for survivors, but also the psychosocial impacts. In the post-treatment phase, the management team must go beyond the realm of 'conventional' follow-up, helping the patient to intellectually understand and emotionally grasp the path ahead. Cancer Survivorship will prove a vital tool to physicians, nurses, clinical social workers and mental health professionals.

Contents:
Cancer Survivors: A Medical Perspective - Cancer Survivors: A Nursing Perspective - Cancer Survivors: A Social Work Perspective - Survivorship Research - Surveillance after Primary Therapy - Late Effects of Cancer Treatments: Surgery, Radiation Therapy, Chemotherapy - Medical and Psychosocial Issues in Childhood Cancer Survivors - Medical and Psychosocial Issues in Hodgkin's Disease Survivors - Medical and Psychosocial Issues in Testicular Cancer Survivors - Medical and Psychosocial Issues in Gynecological Cancer Survivors - Medical and Psychosocial Issues in
Breast Cancer Survivors - Medical and Psychosocial Issues in Prostate Cancer Survivors - Medical and
Psychosocial Issues in Lung Cancer Survivors - Medical and Psychosocial Issues in Colorectal Cancer Survivors - Medical and Psychosocial Issues in Transplant Survivors (AML, ALL, Lymphoma) - Cancer in the Elderly - Second Malignancies after Therapy - Psychosocial Rehabilitation - Reproductive Complications and Sexual Dysfunction - Insurance, Employment, and Job Discrimination.- Cancer Advocacy.